Akkermansia Muciniphila Combined With Infliximab for Promoting Intestinal Mucosal Healing in Crohn's Disease

Starting soon · Phase 4

Conditions studied: Crohn's Diseases

In brief

This study aims to evaluate whether the combination of Akkermansia muciniphila with infliximab can improve intestinal mucosal healing in patients with Crohn's disease compared with infliximab alone.

Key facts

Study ID: NCT07415473
Run by: Chinese Medical Association
People needed: 400
Starts: 2026-04-01
Expected to finish: 2029-03-31
Last updated by the study team: 2026-02-17

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Adult patients aged 18 to 75 years.
Documented diagnosis of Crohn's disease established at any time prior to screening by radiological, histological, or endoscopic evidence.
Active Crohn's disease at screening, defined as a Crohn's Disease Activity Index (CDAI) score between 220 and 450 (inclusive).
Adequate cardiac, renal and hepatic function, as assessed by the investigator based on screening laboratory tests, physical examination, and medical history, without findings that would pose an undue risk for study participation.
Willingness and ability to provide written informed consent.
Agreement to undergo all scheduled study procedures, including up to 3 endoscopic evaluations.

You may not qualify if…

Use of any biologic therapy (e.g., infliximab, adalimumab, ustekinumab, vedolizumab) within 8 weeks prior to screening.
Use of systemic antibiotics or any probiotic preparation within 4 weeks prior to screening.
History of any intestinal resection or other Crohn's disease-related surgery.
History of or active chronic or recurrent infectious disease.
History of or current malignancy.
Pregnancy, lactation, or intention to become pregnant during the study period.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.